(Q37170349)

18 August 2017

1 reference

title

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal (English)

1 reference

18 August 2017

5

A Tefferi

1 reference

18 August 2017

A M Vannucchi

1

1 reference

18 August 2017

E Antonioli

series ordinal

2

1 reference

18 August 2017

P Guglielmelli

series ordinal

3

1 reference

18 August 2017

A Pardanani

series ordinal

4

1 reference

18 August 2017

publication date

22 May 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

22

1 reference

18 August 2017

issue

7

1 reference

18 August 2017

page(s)

1299-1307

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2008.113

18 August 2017

exact match

0 references

cites work

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Oncogenic mechanisms in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Jak2 is essential for signaling through a variety of cytokine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Characterization of murine JAK2V617F-positive myeloproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

The myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Polycythemia vera is not initiated by JAK2V617F mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

The genetic basis of myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Clinical correlates of JAK2V617F allele burden in essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Risk-adapted therapy in essential thrombocythemia and polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

The myeloproliferative disorder associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

7 January 2021

The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

7 January 2021

Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

7 January 2021

Demonstration of MPLW515K, but not JAK2V617F, in in vitro expanded CD4+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

7 January 2021

Inconsistencies in the association between the JAK2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

7 January 2021

Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

7 January 2021

Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

7 January 2021

Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

7 January 2021

The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

7 January 2021

The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

7 January 2021

Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

7 January 2021

JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

7 January 2021

Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

7 January 2021

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

7 January 2021

Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

7 January 2021

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

7 January 2021

Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

7 January 2021

Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

7 January 2021

Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

7 January 2021

The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

7 January 2021

Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

7 January 2021

Interferon alpha induces a good molecular response in a patient with chronic eosinophilic leukemia (CEL) carrying the JAK2V617F point mutation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

7 January 2021

The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.113

7 January 2021

Identifiers

DOI

10.1038/LEU.2008.113

1 reference

Dimensions Publication ID

18 August 2017

1037292092

0 references

Fatcat ID

release_dzpwvdokpfa53hcdhypb2n2ole

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dzpwvdokpfa53hcdhypb2n2ole

24 November 2022

mapped directly with Wikidata item

1 reference